Sanofi-Aventis v. Apotex Inc., 2015 SCC 20, [2015] 2 SCR 136

 

  

 

SUPREME COURT OF CANADA

 

Citation: Sanofi-Aventis v. Apotex Inc., 2015 SCC 20, [2015] 2 S.C.R. 136

Date: 20150420 Docket: 35886

 

Between:

 

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.

Appellants

and

Apotex Inc.

Respondent

- and -

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.

Appellants

and

Apotex Inc.

Respondent

- and -

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.

Appellants

and

Apotex Inc.

Respondent

- and -

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.

Appellants

and

Apotex Inc.

Respondent

and

Canadian Generic Pharmaceutical Association

and Canada’s Research-Based Pharmaceutical Companies

Interveners

 

 

 

Coram:  McLachlin C.J. and Abella, Rothstein, Cromwell, Moldaver, Karakatsanis, Wagner, Gascon and Côté JJ.

 

Reasons for Judgment: (paras. 1 and 2)

McLachlin C.J. (Abella, Rothstein, Cromwell, Moldaver, Karakatsanis, Wagner, Gascon and Côté JJ. concurring)

 

 

 

 

 

Sanofi-Aventis v. Apotex Inc., 2015 SCC 20, [2015] 2 S.C.R. 136

 

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.                                                                  Appellants

v.

Apotex Inc.                                                                                                   Respondent

- and -

 

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.                                                                  Appellants

v.

Apotex Inc.                                                                                                   Respondent

- and -

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.                                                                  Appellants

v.

Apotex Inc.                                                                                                   Respondent

- and -

Sanofi-Aventis, Sanofi-Aventis Deutschland GmbH

and Sanofi-Aventis Canada Inc.                                                                  Appellants

v.

Apotex Inc.                                                                                                   Respondent

and

Canadian Generic Pharmaceutical Association

and Canada’s Research-Based Pharmaceutical Companies                    Interveners

Indexed as: Sanofi-Aventis v. Apotex Inc.

 

2015 SCC 20

 

File No.: 35886.

 

2015: April 20.

 

Present:  McLachlin C.J. and Abella, Rothstein, Cromwell, Moldaver, Karakatsanis, Wagner, Gascon and Côté JJ.

 

on appeal from the federal court of appeal

 

                    Intellectual property — Patents — Medicines — Manufacturer applied to market generic version of drug — Patentees of drug applied for prohibition orders that triggered statutory stay under Patented Medicines (Notice of Compliance) Regulations and prevented manufacturer from selling generic for 24 months — Action for damages brought under s. 8 of Regulations for delayed market entry — Court of Appeal holding that trial judge did not err in determining liability period of 24 months, in determining that patentees’ authorized generic version would have entered market within three months and achieved 30 percent share of hypothetical market within liability period, or in determining that manufacturer entitled to compensation for lost sales of its generic version associated with unapproved indications — Patented Medicines (Notice of Compliance) Regulations, SOR/93-133.

 

                    APPEAL from a judgment of the Federal Court of Appeal (Sharlow, Pelletier and Mainville JJ.A.), 2014 FCA 68, 456 N.R. 279, 125 C.P.R. (4th) 403, [2014] F.C.J. No. 295 (QL), 2014 CarswellNat 700 (WL Can.), setting aside in part the judgment of Snider J., 2012 FC 553, 410 F.T.R. 78, [2012] F.C.J. No. 620 (QL), 2012 CarswellNat 1646 (WL Can.). Appeal dismissed.

 

                    Andrew J. Reddon, Steven G. Mason, David Tait and Sanjaya Mendis, for the appellants.

 

                    Harry B. Radomski, Andrew Brodkin, David Scrimger and Benjamin Hackett, for the respondent.

 

                    Jonathan Stainsby, David W. Aitken and Devin Doyle, for the intervener the Canadian Generic Pharmaceutical Association.

 

                    Allyson Whyte Nowak and Jason Markwell, for the intervener the Canada’s Research-Based Pharmaceutical Companies.

 

                    The judgment of the Court was delivered orally by

[1]                              The Chief Justice — We are all of the view to dismiss the appeal substantially for the reasons of the majority of the Court of Appeal.

[2]                              The appeal is dismissed with costs.

                    Judgment accordingly.

 

                    Solicitors for the appellants: McCarthy Tétrault, Toronto.

 

                    Solicitors for the respondent: Goodmans, Toronto.

 

                    Solicitors for the intervener the Canadian Generic Pharmaceutical Association: Aitken Klee, Toronto and Ottawa.

 

                    Solicitors for the intervener the Canada’s Research-Based Pharmaceutical Companies: Norton Rose Fulbright Canada, Toronto.